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Population Screening for Colorectal Cancer Means Getting FIT: 
The Past, Present, and Future of Colorectal Cancer Screening Using 
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of Medicine, Dundee, Scotland, §NHS Bowel Cancer Screening Southern Programme Hub, Royal Surrey County Hospital and University of 
Surrey, Guildford, UK, and ӑFlinders Centre for Innovation in Cancer, Flinders University, Bedford Park SA, Australia
Fecal immunochemical tests for hemoglobin (FIT) are 
changing the manner in which colorectal cancer (CRC) 
is screened. Although these tests are being performed 
worldwide, why is this test different from its predecessors? 
What evidence supports its adoption? How can this evidence 
best be used? This review addresses these questions and 
provides an understanding of FIT theory and practices to 
expedite international efforts to implement the use of FIT in 
CRC screening. (Gut Liver 2014;8:117-130)
Key Words: Population screening; Colorectal cancer; Fecal 
immunochemical test for hemoglobin; Colorectal cancer 
screening
INTRODUCTION
Colorectal cancer (CRC) is the third most commonly 
diagnosed cancer in men and the second in women.1 Australia, 
New Zealand, Europe, and North America have the highest 
CRC incidence, and Africa and Asia the lowest.2,3 Developing 
countries are witnessing an increasing incidence of CRC that is 
probably related to the adoption of high risk Western behavior 
with increased smoking, high alcohol consumption, physical 
inactivity, and less healthy diets.2,4
CRC mortality rates have declined in many economically 
developed countries but only in the United States has a decrease 
in incidence been described. A large proportion of the observed 
decrease in CRC mortality and incidence is likely to be due to 
screening and so the case to screen is clear, although the choice 
of screening method is not. The design of a screening system 
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will be influenced by many important factors including the 
following:
1) Evidence (peer reviewed publications) that the selected 
approach will be effective in decreasing both CRC mortality and 
incidence.
2) Evidence of cost effectiveness to support the economic and 
political case for a sustainable screening program.
3) Evidence of an effective organizational model that works 
within available resources (financial and human) and provides 
the high volume and high quality organizational analytical and 
clinical services necessary for population-based screening.
4) Evidence of the effectiveness of a suitable primary 
screening test such as fecal immunochemical tests for 
hemoglobin (FIT) and reliable comparative information about 
the analytical and clinical performance of the test.
This review addresses the aspects of the last point: the 
suitability and effectiveness of FIT for population screening.
Recognition of the high burden of CRC has helped make the 
case for national screening programs. Randomized controlled 
trials using guaiac-based fecal occult blood tests (gFOBTs) or 
flexible sigmoidoscopy (FS) have provided convincing evidence 
that organized population-based screening can decrease CRC 
mortality and incidence5-12 and therefore the case for CRC 
screening is very strong.
FIT has gained international acceptance as being the worthy 
successor to the proven gFOBT. It can provide the first step of 
a two-step strategy where a positive FIT precedes a diagnostic 
structural examination such as colonoscopy or computed 
tomographic colonography.13-15 Some in the United States are 
committed to a single step colonoscopy screening strategy 
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because they argue that FIT has little effect on CRC incidence.16 
They claim that the principle of CRC detection using fecal 
tests (gFOBT and FIT) is inherently insensitive and nonspecific 
because the tests detect blood, a surrogate for advanced 
neoplasia, and depend on the relevant neoplasia (cancer and/or 
advanced adenomas) bleeding in sufficient quantities to enable 
detection in feces.17,18 This review provides the evidence that 
supports FIT population-based screening and should help inform 
clinicians, laboratory medicine service providers, health service 
funders, and health policy experts why FIT is the most effective 
noninvasive CRC screening test currently available. The review 
also provides guidance on how to identify suitable FIT systems. 
FIT FACTS
The fecal immunochemical test for hemoglobin with the 
abbreviation FIT was recommended as the preferred name for 
this screening test by a World Endoscopy Organization (WEO) 
Expert Working Party (EWP) in 2012 to avoid confusion with 
gFOBTs and to emphasize the significant analytical and clinical 
differences. FIT should replace terms such as immunological 
fecal occult blood test, immunohistochemical test, etc. as the 
only recommended term. The WEO EWP has chosen not to 
endorse the use of FIT50 or FIT100 as a method of denoting 
both the test name and cutoff concentration because, until 
standardized reporting units have been widely adopted, the 
use of this nomenclature has the potential of misleading 
the reader. Constancy of terminology and reporting units 
aids understanding and transference of ideas and research 
observations across time and geography.
FIT use antibodies specific for human hemoglobin. They use 
the principle that a suitable monoclonal or polyclonal antibody 
can recognize and will bind to the intact globin component of 
human hemoglobin. By using labeled antibodies, the bound 
antibody-hemoglobin complex can be detected and measured 
by a variety of techniques. It can provide a positive or negative 
test result in qualitative FIT or a fecal hemoglobin concentration 
in quantitative FIT systems. Quantitative FIT are the test 
of choice for population screening since they can provide 
consistently high quality, automated measurements using high 
performance analytical systems that will enable selection of the 
preferred fecal hemoglobin cut-off concentration above which 
the risk of CRC merits colonoscopic investigation. Quantitative 
FIT thus allow the screening program the opportunity to select 
an acceptable sensitivity/specificity balance and the ability 
to ensure that colonoscopic referral rates can be met by local 
circumstances, particularly the available colonoscopic resources. 
While gFOBT and FIT share the same clinical detection 
principle (bleeding) and biomarker (hemoglobin), the analytical 
methods are very different. gFOBT detects the presence of 
blood’s heme component when hydrogen peroxide is added 
during analysis and oxidizes guaiac to form a blue colored dye. 
Intact heme enables oxidation and is responsible for the clinical 
efficacy of gFOBT. Although gFOBT are cheap and simple tests, 
they require a significant quantity of heme to effect a visible 
change in color and are therefore not very sensitive analytically 
to the presence of blood. The method relies on simple oxidation, 
and therefore any dietary hemoglobin in red meat etc., has the 
potential to give a false positive result, as can drugs or foods 
that have peroxidase properties (i.e., some uncooked fruits and 
vegetables). Antioxidants in drugs or foods (vitamin C or E) also 
have the potential to give false negative results by interfering 
with the oxidation of guaiac. The gFOBT is therefore an 
inherently insensitive and nonspecific test.
FIT detect blood by immunoassay. An antibody is prepared 
that specifically recognizes the globin component of human 
hemoglobin. FIT analysis measures the quantity of antibody 
bound to hemoglobin using a variety of methods. The FIT 
technique is analytically sensitive to low concentrations 
of hemoglobin and is unlikely to be subject to significant 
interference from other constituents of feces.
Substantial clinical benefits are possible because of the 
superior analytical technique used in FIT. Sensitive and specific 
analysis for hemoglobin means that FIT can detect smaller levels 
of bleeding and thus smaller cancers and more adenomas and 
the number of false positives is reduced for a given hemoglobin 
concentration. As will be discussed later, the enhanced clinical 
sensitivity and specificity of FIT is maintained even when 
the performance of a single-sample FIT is compared with the 
traditional three-sample gFOBT. While the heme component of 
hemoglobin is a relatively robust molecule and it can survive 
with its oxidative properties intact even after traversing the full 
length of the gastrointestinal (GI) tract, the globin detected by 
FIT is prone to degradation from GI proteases. This property 
adds significant organ specificity to the list of clinical merits of 
FIT and makes it is less likely to present false positive results 
from upper gastrointestinal tract bleeding than might be rarely 
observed by gFOBT.
FIT products have two general designs that use different 
analytical techniques, lateral flow immunochromatographic 
analysis and immunoturbidimetric analysis. Most qualitative 
products are designed for use at the point-of-care, outside of 
a laboratory and by clinicians. These tests use the ubiquitous 
lateral flow immunochromatographic system adopted for most 
pregnancy tests and many point-of-care tests (POCTs) for 
drugs and hormones. This system separates soluble hemoglobin 
from feces using passive flow (laterally) along a separation 
material (chromatographic) for the hemoglobin to be captured 
by antibodies to human hemoglobin and made visible using 
various visualizing techniques (Fig. 1). The manufacturer can 
adjust the visibility of the line that shows the presence of 
hemoglobin, essentially changing the cutoff concentration 
that will lead to further investigation, but it requires skill and 
practice to obtain consistency in visual interpretation.
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Quantitation requires laboratory technology and immunoturbidimetry 
is one of several immunoassay techniques well established in 
clinical laboratories. It introduces the challenge of collecting 
a small fecal sample and transporting it to the laboratory. 
Different FIT use different approaches to controlling sample size 
and none is particularly good at doing it accurately. Accurate 
results also require FIT manufacturers to ensure sample stability 
and they go about it in different ways with varying success. 
FIT technology provides the opportunity to address several 
important practical screening issues. A screening test only has 
merit if the uptake by the invited population is acceptable. 
Screening participation with FIT has been found to be 
consistently higher than with gFOBT.19,20 The evidence was 
recently described in a systematic review and meta-analysis and, 
in addition to pointing out the merits of FIT, it concluded that 
more research examining FIT from a participant perspective was 
warranted.21 The relative merits of using FIT rather than gFOBT 
include improved participation rates because FIT typically use 
only a single fecal sample instead of the three required for 
gFOBT. The FIT specimen collection system described earlier 
is simple to use and is less messy than gFOBT cards and, once 
the sample probe has been returned to the collection device, 
the feces is safe and out of sight. Unlike the 3-sample gFOBT 
card system, once the single FIT sample collection is complete 
it can be returned immediately for testing and the participant 
has no need to store and handle a gFOBT card laden with feces. 
From an aesthetic perspective the FIT device appears modern, 
scientific, and clinical, unlike the simple gFOBT card.
A challenge for all screening programs is to reduce the 
socioeconomic gradient seen in the uptake of CRC screening. A 
recent study in Scotland described the impact on participation of 
changing from gFOBT to FIT and showed the greatest increase 
in FIT uptake was in men, younger participants, and individuals 
in the lower socioeconomic strata, all groups for which uptake 
is generally poor.22 In the United States, the introduction of 
screening using FIT in clinics and hospitals that care for all 
patients regardless of their socioeconomic and insurance status 
(e.g., San Francisco General Hospital and the Alameda County 
Medical Center) has greatly increased screening rates (personal 
communication).
FIT that are suitable for population screening are best 
measured on automated analytical systems. These enable 
fast and reliable analysis and remove the subjective visual 
assessment that is a severe limitation to consistent and reliable 
screening with gFOBT and qualitative FIT (Fig. 2).23-25
Quantitative FIT provide the concentration of hemoglobin 
in feces and studies have consistently shown that this 
concentration is related to both detection rate and to the 
severity of the lesion. By adjusting the cutoff concentration 
upwards positivity decreases, fewer colonoscopies are performed 
and fewer lesions (but proportionally more advanced lesions) 
are detected. This approach has been trialed in Scotland using a 
very high cutoff chosen to provide the same positivity as their 
gFOBT and, while its positive predictive value for cancer was 
not improved significantly, it did improve participation rates.26 
Conversely, where colonoscopy resource is not a limitation, 
the sensitivity of FIT can be increased by adjusting the cutoff 
concentration to a lower fecal hemoglobin concentration. 
FIT brings both practical and clinical advantages to 
population screening and some of those advantages have 
yet to be fully exploited. No longer do we determine the 
risk of a cardiac event just from cholesterol concentration 
measurement―we include other measured variables including 
age, sex, body mass index (BMI), smoking, family history, etc., 
and the same applies to staging the severity of kidney disease. 
With a quantitative FIT we can do the same and bring together, 
in a multivariate risk score, other accessible risk factors such 
as age, sex, family history, screening history, and perhaps BMI 
and smoking etc. Quantitative FIT opens opportunities for major 
enhancement to the current binary risk (positive or negative) 
outcome offered by gFOBT and is an approach that has been 
recently described by Stegeman et al.27
FIT Performance Is Superior to gFOBT: The Evidence
Simon, in an early review of fecal occult blood testing, states 
that research on FIT began in the late 1970s.28 In the 1970s, 
Fig. 1. Cartoon illustrating lateral flow immunochromatographic 
analysis principle of a fecal immunochemical test for hemoglobin.
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Barrows et al .29 and Songster et al .30,31 and their coworkers 
developed an immunochemical test for occult blood that, unlike 
gFOBT, detected human hemoglobin free of cross-reactivity with 
animal hemoglobin and other dietary constituents. They then 
adapted the test for CRC screening by using a simple punched-
out filter paper disc on which the fecal specimen was placed 
for development. In 1981, an immunofluorescent test for fecal 
occult blood was described by Vellacott et al.32
FIT were first used in the 1980s for screening in Japan. 
Research with FIT was subsequently described in Australia,33,34 
England,35 Israel,36 and the United States37,38 in the 1990s and 
was followed from 2005 by a progressively large body of 
literature that described the clinical benefits of FIT relative to 
gFOBT.39-43 These studies showed that FIT provided a superior 
sensitivity/specificity for advanced colorectal neoplasia (cancer 
and advanced adenomas) over that provided by gFOBT and, 
because they identified a significant proportion of advanced 
adenomas as well as CRC, it became clear that they offered the 
potential for decreasing both mortality from and incidence of 
CRC.
In the United States, the federal U.S. Food and Drug 
Administration (FDA) approved the use of a qualitative FIT 
system in 1988, and another in 1996, but it did not and has still 
not approved the use of quantitative FIT. Outside of the United 
States a plethora of qualitative and several quantitative FIT are 
now available and several quantitative FIT are now used in 
national screening programs.
Despite the fact that FIT have been available since the late 
1970s, it was not until the late 1990s and the early 2000s, that 
the English language scientific literature on FIT performance 
characteristics became robust. Much of the later research 
has been conducted in Japan, Italy, Israel, Australia, The 
Netherlands, Germany, Korea, and the UK where population-
based screening programs have or are being developed. The 
FDA restrictions in the United States and the promotion of 
colonoscopy as the “best” and “preferred” CRC screening test 
modality has continued and has stifled both FIT research and 
the implementation of United States-based population screening 
programs.44
Acceptance of FIT as an important screening test for CRC 
began in the 1990s in Japan, Australia, the United States, 
Israel, and Scotland where studies demonstrating their 
performance characteristics and cost effectiveness were first 
published.33,35-38,45-47 Though the studies varied in design, 
numbers, population screened, and FIT product used, all 
demonstrated the superior performance characteristics of FIT 
to the commonly used low sensitivity gFOBT. A convincing 
demonstration of FIT superiority to both the standard and 
sensitive guaiac fecal occult blood test (sFOBT) was performed 
in a Kaiser Permanente facility in northern California and 
published in 1996.37 Test sensitivity (result of testing a screening 
population once only) was estimated by performing long-
term follow-up (2 to 4 years) of test-negative participants as 
suggested by Cole and Morrison.48 Test-negative subjects who 
developed CRC or advanced adenomas were identified through 
a search of the computer databases at the Kaiser Permanente 
Northern California Regional Cancer Registry Project and the 
pathology departments at the participating medical centers.
By 2010, the evidence of FIT superiority over the standard 
gFOBT was clear and sufficiently convincing for the European 
guidelines for quality assurance in CRC screening and diagnosis 
to recommend adoption of FIT in preference to gFOBT.13,14 In 
a 2006 Israeli study, FIT sensitivity for advanced neoplasms 
was similar to that for gFOBT but FIT had better specificity and 
positive predictive value.49 In a 2007 Kaiser Permanente study, 
FIT performance characteristics were compared with those of the 
Fig. 2. Variable positivity rates of 
well-trained, well-supervised, and 
well-monitored analysts based on 
their guaiac fecal occult blood test 
results.
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high sensitivity guaiac FOBT (sFOBT) for identifying left-sided 
colorectal advanced neoplasms in a large group of average risk 
individuals. All participants with negative tests were encouraged 
to have a flexible sigmoidoscopy (FS). Sensitivity for left-
sided CRC was 82% for FIT and 64% for the sFOBT (Table 1).39 
In 2008 the Dutch published the first randomized comparison 
between gFOBT and FIT in an average risk screening 
population.43 In this study the number needed to scope to 
find one CRC was not different between gFOBT and FIT but 
participation and detection rates for advanced adenomas and 
cancer were significantly higher in the group tested with FIT: 
2.5 times more advanced adenomas and cancer and 2.2 times 
more cancers were detected with FIT compared with gFOBT. The 
authors concluded that gFOBT significantly underestimated the 
prevalence of advanced adenomas and cancer compared with 
FIT in a screening population (Fig. 3). A study published in 2010 
demonstrated similar findings in a Korean population.42 Based 
on this accumulated knowledge of population screening with 
FIT, an editorial published in Gut in 2012 suggested that the use 
of gFOBT for CRC screening was a less effective and obsolete 
strategy.50
The Preferred Worldwide Screening Test Options for 
CRC 
Of the many CRC screening tests available only four are 
used in national, regional, and local screening programs 
and they are gFOBT, FIT, FS, and optical colonoscopy. Only 
traditional gFOBT5-7 and FS8-11 have been shown to decrease 
CRC mortality and/or incidence in randomized controlled 
trials. Fletcher reviewing a FIT study for the ACP Journal Club 
in 1996 stated that although randomized controlled trials of 
FIT have not been undertaken to show that FIT decreases CRC 
mortality and incidence, they are unnecessary since FIT has 
demonstrated superior performance characteristics to gFOBT.51 
As described earlier, FIT like gFOBT use detection of occult fecal 
blood in feces to identify those screened subjects most likely to 
harbor advanced neoplasia. FIT provide a significant analytical 
enhancement to the same biomarker. In the same way that we 
did not reappraise the use of electrolyte measurements when 
clinical laboratories moved from flame photometry to ion 
specific electrodes or glucose when we moved from colorimetric 
to enzymatic measurement, we have no need to reappraise the 
use of FIT; clinical effectiveness has already been demonstrated.
Studies like those recently published in Australia, show 
down-staging of CRC in a population study, a surrogate 
measure for effect of screening on mortality52 and preliminary 
data from Italy53 and Taiwan, suggest a reduction in incidence. 
In the absence of randomized controlled trial evidence for a 
screening test’s effectiveness in decreasing CRC mortality and 
incidence, investigators frequently turn to modeling studies. A 
2008 study showed years of life saved through a high-quality, 
Table 1. Performance Characteristics of Fecal Immunochemical Test for Hemoglobin versus Guaiac-Based Fecal Occult Blood Test for Left Sided 
Advanced Neoplasms
Finding per test
No. of 
persons 
screened
No. of 
neoplasms 
detected
Sensitivity Specificity
Positive predictive
value
Likelihood
ratio (+)a
No./total % (95% CI) No./total % (95% CI) No./total % (95% CI) Ratio 95% CI
Distal cancer
Sensitive guaiac test 5,799 14 9/14 64.3
(35.6-86.0)
5,210/5,785 90.1 
(89.3-90.8)
9/584 1.5 (0.8-3.0) 6.5 4.3-9.6
FIT 1 5,356 11 9/11 81.8 
(47.8-96.8)
5,181/5,345 96.9 
(96.4-97.4)
9/173 5.2 (2.6-10.0) 26.7 19.4-36.6
Distal adenomas ≥1 cm
Sensitive guaiac test 5,799 126 52/126 41.3 
(32.7-50.4)
5,141/5,673 90.6 
(89.8-91.4)
52/584 8.9 (6.8-11.6) 4.4 3.5-5.5
FIT 1 5,356 112 33/112 29.5 
(21.4-38.9)
5,104/5,244 97.3 
(96.8-97.7)
33/173 19.1 (13.7-25.9) 11.0 7.9-15.3
Distal advanced neoplasms
Sensitive guaiac test 5,799 137 59/137 43.1 
(34.7-51.8)
5,137/5,662 90.7 
(89.9-91.5)
59/584 10.1 (7.8-12.9) 4.6 3.8-5.7
FIT 1 5,356 121 40/121 33.1 
(24.9-42.3)
5,102/5,235 97.5 
(97.0-97.9)
40/173 23.1 (17.2-30.3) 13.0 9.6-17.6
Adapted from Allison JE, et al. J Natl Cancer Inst 2007;99:1462-1470, with permission from Oxford University Press.39
CI, confidence interval; FIT, fecal immunochemical tests for hemoglobin.
aLikelihood ratio (+)=sensitivity/(1-specificity).
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high sensitivity, occult blood screening program are the same 
as with a high-quality colonoscopy screening program.54 Based 
on this modeling study and the accumulated evidence of FIT 
screening being effective for identifying patients with advanced 
adenomas, the American College of Physicians, the National 
Colorectal Cancer Roundtable, the American Cancer Society, 
and the Journal of the American Medical Association have all 
issued statements that evidence does not yet support any one 
screening test over another and that the currently available CRC 
screening tests mentioned above are believed to be similarly 
efficacious.55-57
Individual countries and/or health organizations need to 
consider the four currently recommended screening modalities 
for feasibility and public acceptability and should undertake well 
designed pilot studies before committing to implementation. 
The United States has no national CRC screening program but 
many screening thought leaders and the media have promoted 
the use of colonoscopy since 2000. Poland and Germany, 
however, are the only countries to have formally embraced 
colonoscopy screening but with mixed results. The evidence 
supporting colonoscopy is expert based and it will be years 
before results are available from two randomized controlled 
trials (United States and Spain) that are comparing annual or 
biennial FIT with optical colonoscopy every 10 years. Results 
from the first round of screening in the Spanish study were 
published in 201258 and had some very interesting findings. 
Subjects in the FIT group were more likely to participate in 
screening than were those in the colonoscopy group and the 
numbers of subjects in whom CRC was detected were similar in 
the two study groups. Although more adenomas were detected 
in the colonoscopy group, this is no surprise. It is well known 
that structural examinations identify more adenomas at initial 
screen but, since adenomas are not malignant and FIT screening 
is advised annually or biennially, there should be confidence 
that a program of repeated screens will allow for identification 
of most of those few adenomas likely to become fatal cancers.
FIT Important Issues: Present and Future
What issues should influence the choice of a FIT and how 
reliable and safe are these devices in practice? While many 
FIT are available on the market, most are designed for use at 
POC and only a few currently meet criteria that we consider 
important for population-based screening and even fewer have 
Fig. 3. Flow chart from invitation 
to detection with numbers, percent-
ages, and 95% confidence intervals 
between brackets. Adapted from 
van Rossum LG, et al. Gastroenter-
ology 2008;135:82-90, with permis-
sion from Elsevier.43
gFOBT, guaiac-based fecal occult 
blood test; FIT, fecal immunochemi-
cal test for hemoglobin.
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been used in large-scale screening.
FIT is a developing test and the WEO EWP, FIT for screening, 
has and is contributing to this development. The issues described 
below illustrate how FIT has evolved into a mature screening 
test. It highlights aspects of FIT technology and clinical 
application that are worthy of consideration prior to designing 
a FIT-based screening program or issuing tender documents for 
FIT procurement. These issues have been the subject of several 
recent editorials, many describing the recommendations of the 
WEO EWP.59-63
1) FIT terminology and the units used for reporting are 
inconsistent and need to be standardized so that published FIT 
studies are amenable to comparison.
2) The stability of hemoglobin in the specimen collection 
devices needs to be characterized in a standardized way so that 
products can be compared and judgments can be made on their 
suitability for screening in different environments and under 
different climatic conditions.
3) FIT need to be easy to use if they are to be accessible to 
the target population. We need to be conscious of poor uptake 
amongst disadvantaged groups and of the effects that aging, 
learning and physical disabilities and poor eye sight might have 
upon participation rates. For FIT and FIT screening programs 
to be clinically effective participation in multiple FIT screening 
rounds is essential.
4) The evidence for clinically effective single FIT biennial 
screening is good, but the option for multiple samples and/or 
alternative screening frequency remains.
5) FIT encourage a choice between local surgery or clinic-
based POCT and the use of centralized, automated accredited 
laboratories using qualitative or quantitative FIT.
6) More well designed and comparative, analytical and 
clinical effectiveness studies will help identify FIT products 
eligible for consideration for population screening.
7) Quantitative FIT results provide opportunities to enhance 
risk stratification, better exploit endoscopy resources, and 
maximize clinical effectiveness.
The following sections discuss each of the above issues.
1. FIT terminology and reporting units
Manufacturers of quantitative FIT have, until recently, reported 
the concentration of hemoglobin dissolved in the devices’ 
collection buffer (ng hemoglobin/mL buffer). This concentration 
is dependent upon the mass of feces added to the buffer and 
the volume of buffer in which it is dissolved. While this enables 
comparison in studies with a single FIT, the data cannot 
be compared with data from other FIT.59 The solution is to 
standardize the units used and adopt hemoglobin concentration 
in feces (μg hemoglobin/g feces).62,64 Manufacturers have 
agreed to adopt these standardized units and the WEO EWP is 
currently preparing a recommended method to standardize how 
manufacturers and others should determine the average fecal 
mass collected by a device and added to the buffer. Clearly, a 
standardized process and material is necessary because the term 
currently used, average fecal sample, is a description without 
practical meaning.
By using a quantitative FIT, the screening program can 
select a cutoff fecal hemoglobin concentration appropriate 
to its resources and target clinical outcomes. Qualitative 
FIT do not provide this option since such FIT use lateral 
immunochromatographic devices on which the positivity 
marker becomes visible. The concentration at which the marker 
becomes positive is determined by the manufacturer and is 
affected by the visual skills of the device reader. The cutoff of 
each qualitative FIT needs to be stated by manufacturers and 
provided in μg hemoglobin/g feces.
While the adoption of a common reporting unit will help 
comparison, it will not make FIT products the same. The 
antibodies are likely to show marginal differences between 
manufacturer and the conditions of analysis will also 
contribute to reporting differences, although the adoption of a 
calibration preparation which has itself been calibrated against 
an internationally agreed hemoglobin standard will reduce 
reporting variation and begin to harmonize results. The WEO 
EWP has recommended that all calibrants should be traceable to 
an internationally recognized standard (e.g., the World Health 
Organization or the International Committee for Standardization 
in Haematology), a standard that has already been adopted by 
most manufacturers.
2. Fecal hemoglobin stability
The heme and the globin components of hemoglobin degrade 
at different rates in the intestines. The iron containing heme 
degrades slowly but the protein globin is subject to more rapid 
enzymatic proteases action. Since FIT analysis depends on 
antibodies binding to globin, it is more susceptible to false 
negative results if samples are not adequately preserved. In 
2009, the government of Australia had to temporarily suspend 
invitations to participation in the National Bowel Cancer 
Screening Program after problems were found in the buffer of 
the FIT kits that were distributed between December 2008 and 
May 2009. The buffer in the FIT specimen collection device was 
not sufficiently effective at minimizing hemoglobin degradation 
at high temperatures. As a result, the collection devices returned 
for analysis yielded a lower than expected proportion of positive 
results, which increased the likelihood that some participants 
would receive false negative results. The potential for inaccurate 
FIT results during hot weather was investigated in Italian 
retrospective studies and showed hemoglobin concentrations 
17% higher in the winter when 13% more cancers were 
detected.65 In The Netherlands the observation of a seasonal 
variation was confirmed by demonstration of an average fall in 
FIT positivity from 10% to 6%.66 Since 2011, companies have 
been actively enhancing the effectiveness of their preservative 
124  Gut and Liver, Vol. 8, No. 2, March 2014
buffers, using antibacterial and stabilizing agents and a 2013 
UK National Health Service evaluation report has shown 
minimal deterioration in samples stored at temperatures up to 
25oC in four quantitative FIT products.67
Dry sampling in FIT systems reduces the rate of microbial 
and enzymatic degradation but it is not consistent across all 
samples and requires significant additional processing of the 
FIT on arrival in the laboratory. As the UK study has shown, FIT 
sample stability is less likely to be a problem as the new more 
effective stabilizing buffers are introduced. 
3. Maximizing FIT uptake and adherence
Many studies have demonstrated that the uptake and 
adherence rates in screening programs using FIT are better than 
in screening programs using gFOBT. Two Dutch cohort studies 
reported by van Rossum et al.43 and by Hol et al.68 illustrate the 
difference. They compared gFOBT/FIT uptake rates and showed 
47% and 60% respectively in one43 and 49.5% and 61.5% 
respectively in the other.68
A problem for all fecal-based (gFOBT or FIT) screening is 
that maximal clinical benefit requires good initial uptake rates 
that are maintained over multiple screening rounds, annually 
or biennially. In 2009, good adherence (85%) over three rounds 
using gFOBT every 2 years was reported in Scotland69 thus, it 
is not surprising that similar uptake and adherence has been 
reported in FIT screening programs over two rounds. Two Dutch 
studies70,71 have shown uptake and adherence after two rounds 
of FIT testing to be from 63% to 86% (Table 2).71 An Italian 
study evaluating the outcome of four rounds of FIT screening 
over 7 years showed an adherence rate of 48% for all four 
rounds, with participation in each round ranging from 56% to 
63%.72
Several investigators have examined ways to improve 
participation and a major national study in England is 
examining general physician endorsement, the use of narrative 
leaflets, and enhancing the information content of reminder 
letters. In the United States, Potter et al.73-76 have developed and 
promoted a unique and successful way to increase FIT uptake 
and participation by using trained clinical teams to offer FIT 
at the same time as patients receive their annual influenza 
vaccinations (Table 3).77 It has been known for a long time 
that endorsement by the primary care practitioner consistently 
improves participation in screening for CRC.78,79
4. Determining the number of FIT samples necessary for 
best results and participant acceptance
There are only a few studies that can help resolve this 
challenging issue. A study reported in 2011 by van Roon et al.80 
is the most comprehensive study yet undertaken to examine the 
value of more than one sample FIT testing at a range of cutoff 
fecal hemoglobin concentrations. It examined participation 
and clinical outcomes with one or two FIT after changing the 
FIT cutoff and by using the two FIT results individually and 
together. It observed no difference in participation rate when 
requesting completion of one or two kits and concluded that, 
for the detection of advanced adenomas, a single FIT performed 
as well as two, unless colonoscopy capacity was particularly 
high or low when the use of two FIT might prove beneficial.
5. FIT measurement and interpretation: POCT or central 
laboratory?
In the United States, FIT manufacturers mostly market 
FIT as POCT devices but there is little or no training, quality 
control monitoring, or oversight of procedures in place to 
give confidence in the reliability of the result and in the 
interpretation of the test result. Although qualitative FIT might 
Table 2. Participation Rates and Advanced Neoplasia Detection Rates 
at Round 2 of Participants in a FIT Screening Program Screened at 
Intervals from 1-3 Years
Characteristic After 1 yr After 2 yr After 3 yr
Participation 63.2 62.5 64.0
Positivity 5.1 6.8 5.6
Detection rate
Advanced neoplasia 1.6 2.1 1.6
Positivity and advanced neoplasia is at the second screening visit 
(R2) for those who participated in the first screening visit (R1). Data 
are presented as percentage. Adapted from van Roon AH, et al. Gut 
2013;62:409-415, with permission from BMJ Publishing Group Ltd.71
FIT, fecal immunochemi cal test for hemoglobin.
Table 3. Increased, Updated Screenings from Individuals Who Were Offered FIT Concurrent with Their Annual Flu Shots
Data for 6 SFDPH clinics participating in the FLU-FOBT RCT No. of flu shot recipients CRCS up to date among flu shot recipients, no (%)
2008/9 (1 yr before) 3,260 1,385 (42.5)
2009/10 (intervention yr) 3,634 1,982 (54.5)
2010/11 (1 yr later) 4,333 2,440 (55.8)
Increased number of flu shots given and the number and proportion of flu shot recipients becoming up to date with colorectal cancer screening 
(CRCS). CRCS up to date defined as having fecal occult blood tests (FOBT) within 12 months, flexible sigmoidoscopy within 5 years or colonos-
copy within 10 years. Adapted from Walsh JM, et al. Health Educ Res 2012;27:886-894, with permission from Oxford University Press.77
FIT, fecal immunochemi cal test for hemoglobin; SFDPH, San Francisco Department of Public Health; FLU-FOBT, primary care intervention pairs 
in the offering of FOBT with yearly influenza vaccine activities; RCT, randomized controlled trial.
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be considered simple to use, and they all contain some form of 
integral control, the color development is dynamic and reading 
time is critical because delayed reading may give false positive 
or false negative results. The skill and visual acuity of a trained 
operator is important if detection of trace positive test lines on 
the immunochromatographic FIT devices is to be consistent. 
External quality assessment and performance monitoring forms 
an important part of good laboratory practice and this must be 
extended to POCT if a POCT-based screening program is to be 
reliable and effective.
6. Analytical and clinical effectiveness studies of different 
FIT
It is normally possible to determine clinical effectiveness of 
a new device or method by a thorough analytical assessment 
followed by comparison with an assessment of a similar 
device of known analytical characteristics and established 
clinical performance. A new FIT would therefore require an 
in-depth assessment of the product’s analytical performance, 
an assessment of the presentation of the device to the invited 
subject, a review of the product design, ease of use and 
associated literature, and then a comparison of the data with 
that of a similar device with known analytical and clinical 
performance characteristics. This principle is well established 
for introducing new analytical devices and new test methods 
into clinical laboratories. The principle is less robust when 
innovative products are introduced and comparison data are not 
available. Innovative products or products that are significantly 
different from those already in use require thorough analytical 
assessment followed by clinical trials or pilots. FIT is such a 
technology; it uses a well-established biomarker (hemoglobin) 
which has been subject to at least four randomized controlled 
trials and it improves the detection system in a way that 
not only enables it to be more sensitive and/or specific but 
introduces the opportunity to detect advanced adenomas as well 
as cancers.
When choosing a quantitative FIT for a screening program 
we recommend those which have been well characterized 
both analytically and clinically and are suitable for use in 
comparative assessment of other similar devices. Decisions 
should be made with the knowledge of potential deficiencies 
such as sample stability reported in the Dutch and Italian 
studies cited above. More studies comparing FIT performance 
in large average risk populations are needed. One such study 
from France was published recently.81 The recent evaluation of 
the four quantitative FIT products with potential for population 
screening in the NHS Cancer Screening Program will help to 
select a FIT for national adoption.67
The selection of FIT products is only the beginning and close 
monitoring with quality control and assessment programs are 
necessary if FIT results are going to meet the quality standards 
required for population screening. While accredited laboratories 
with appropriate ISO standards will provide confidence for 
quantitative FIT, maintaining high quality for POCT qualitative 
FIT is a challenge, particularly if the test is being performed 
on many sites across a large geographical area. Consideration 
needs to be given, prior to the development of a new screening 
program, to systems for external quality monitoring of the 
analytical performance of POCT FIT and how poor performance 
will be managed. Real time monitoring of test outcomes in 
screening programs is important and was what alerted the 
Australian program to a problem with sample stability.
7. Which FIT (qualitative or quantitative) are best for 
population screening?
The issue of qualitative versus quantitative FIT has been 
visited throughout this review. Qualitative FIT are not well 
suited to organized population-based screening programs 
which have at their core, common, and consistent processes, 
close monitoring of performance data, audit and a general 
emphasis on high performance quality, economies of scale, and 
cost effectiveness. Activities are generally centralized and the 
opportunity for individual preference is minimal. Qualitative FIT 
cannot take advantage of the ability of quantitative FIT to select 
and adjust fecal hemoglobin cutoff concentrations; it cannot 
therefore adjust positivity rates to meet endoscopic resource 
or select target clinical sensitivity or positive predictive value. 
It cannot fully exploit the relationship between hemoglobin 
concentration and severity of the lesion to maximize detection 
nor can it easily adopt a sophisticated multivariate risk 
stratification model which is likely to demand ready access to 
participant clinical and screening history for risk computation.
The advantage of qualitative FIT is that, in the absence 
of an organized screening program and at minimal cost to 
an individual, a simple noninvasive screen for CRC can be 
performed. It is potentially, and perhaps superficially, a more 
personal and appealing method of screening and evidence 
shows that a motivated primary care physician (PCP) is an 
effective advocate for screening and will increase screening 
participation. Effective replication across a population with less 
motivated PCPs presents a challenge.
The likely total cost of population-based screening using 
qualitative FIT will be greater than that of organized screening 
using an automated high volume quantitative FIT system if full-
cost analysis is undertaken. For most health systems, the cost 
of the test will be small alongside the cost of clinical services. 
Quantitative FIT provide the tools to control colonoscopy 
referrals. For qualitative tests, the referral rates are dictated 
by the manufacturer’s embedded fecal hemoglobin cutoff 
concentration.
We advocate the use of quantitative, automated FIT over 
qualitative FIT (especially those without automation). The 
evidence to support the opportunities for more effective 
screening strategies using quantitative FIT is still growing and 
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an editorial by Imperiale82 on a 2007 Israeli study40 showed 
that the mean fecal hemoglobin value increases in a clinically 
important and statistically significant way as the neoplastic 
finding advanced from normal to nonadvanced adenoma to 
advanced adenoma to cancer (Table 4, Fig. 4). As discussed in 
a recent editorial,83 these FIT have the advantage of being able 
to be modified for use in countries with nationally organized 
screening programs where cutoff hemoglobin concentration(s) 
can be determined to meet preset objectives and available 
financial and endoscopy resources. In the United States, the U.S. 
Food and Drug Administration has yet to approve quantitative 
FIT products.
8. Setting cutoff concentrations
In current practice, a single cutoff fecal hemoglobin 
concentration is used with quantitative FIT to divide the 
population into those who require follow-up, usually by 
colonoscopy, and those who do not. This practice does not 
exploit the full potential of quantitative FIT that can enable 
individualized tuning of the screening strategy applied. Other 
factors like age, sex, screening and family history, BMI, 
alcohol consumption, smoking, etc. also contribute to the 
likelihood of a significant neoplasm and, with quantitative 
FIT, these parameters can be explored to find a multivariate 
risk model that could provide enhanced risk stratification 
enabling more clinically and cost effective endoscopy referrals. 
As mentioned in FIT facts above, a recent publication from 
The Netherlands demonstrated that by combining risk factors 
with FIT in a multivariate risk score and referring higher risk 
patients for colonoscopy (a total of 102) rather than just those 
with a positive FIT, five more cases of advanced neoplasia 
would be identified.27 The Dutch study showed that while FIT 
concentration was the major contributor to their risk model, 
age, calcium intake, family history of CRC, and past or current 
smoking were all contributors but that BMI, menstrual status, 
fiber intake, aspirin/nonsteroidal anti-inflammatory drug use, 
and red meat intake were not significant.
Screening programs using FIT and gFOBT have shown major 
age and sex differences in fecal hemoglobin concentrations. In a 
randomized trial of gFOBT versus FIT, the positivity rate and the 
detection rate for all colorectal neoplasia was higher for men 
than women and higher for those aged 60 years and above.43 
In a study on the effects of sex on FIT, it was found that at any 
cutoff for hemoglobin concentration, sensitivity, and positive 
predictive value were substantially higher, and the specificity 
and negative predictive value were substantially lower among 
men than women.84 The authors of the study raise the issue of 
a program having a different cutoff concentration for men and 
women, an arrangement that is commonplace for reference 
ranges used in clinical laboratories. It has been suggested that 
similar findings on sex and age mean that there is a need for 
more tailored screening strategies.85
SUMMARY AND CONCLUSIONS
In 2014, it can no longer be argued that FIT is incapable of 
decreasing both CRC mortality and incidence in a screening 
population nor that fecal hemoglobin is an unsuitable marker 
for screen-relevant neoplasia. FIT is recognized by most 
countries with CRC population-based screening programs as 
the best screening test.14 FIT bring many advantages to CRC 
screening, presents new challenges and offers opportunities 
for further enhancement to screening programs. While new 
noninvasive tests will be developed, FIT is currently the test of 
Table 4. The Quantitative FIT for Hemoglobin Results Showed a Direct Correlation between the Amount of Blood in the Stool and the Occurrence 
of Advanced Neoplasms (Cancer and Advanced Adenomas)
Characteristic Patients, no (%)
Lesion size, mm Mean FIT result, ng/mL
Mean±SD 95% CI Mean±SD 95% CI
Normal 739 (73.9) 35±143 25-45
  Advanced adenoma 74 (7.4) 12.6±6.4 11.2-14.1 485±744 315-654
   Colon site
    Proximal 31 (12.7) 12.4±6.8 10.1-14.7 499±774 227-772
    Distal 42 (17.2) 12.9±6.2 11.0-14.7 501±737 279-724
Cancer stages
    Dukes A and B 15 (88.2) 30.7±9.3 26.0-35.4 1,045±777 652-1,439
    Dukes C and D 2 (11.8) 50.0±7.1 40.2-59.8 1,399±1,452 614-3,411
Colon site
    Proximal 10 (58.8) 33.8±10.3 27.4-40.2 701±672 285-1,118
    Distal 7 (41.2) 31.7±12.5 22.4-41.0 1,637±720 1,104-2,171
Adapted from Levi Z, et al. Ann Intern Med 2007;146:244-255, with permission from American College of Physicians.40
FIT, fecal immunochemical test for hemoglobin; CI, confidence interval. 
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choice and is the biomarker test against which new tests must 
be compared and assessed.
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